000			02937cam a2200325 a 4500
003			EG-GiCUC
008			210801s2020 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.15.M.Sc.2020.Mo.G
100	0		_aMostafa Ahmed Hani Ebrahim
245	1	0	_aGnRH agonist trigger versus hcg trigger in GnRH antagonist in IVF/ICSI cycles in female with PCO / _cMostafa Ahmed Hani Ebrahim ; Supervised Fouad Abdelkader Abohamila , Wafaa Ramadan Abdelrazik , Mohamed Ahmed Bahaa
246	1	5	_aفى النساء التى تعانى من تكيسات على المبيض (GnRH antagonist) كمحفز لنضج البويضات النهائي وتحريرها في دورات الحقن المجهري المستخدم فيها البروتوكول المضاد (hCG)و (GnRH agonist) مقارنة بين استخدام
260			_aCairo : _bMostafa Ahmed Hani Ebrahim , _c2020
300			_a78 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Gynecology and Obstetrics
520			_aWith a steady increase in the number of assisted reproductive technology (ART) cycles over the years, there has been an increase in the incidence of ovarian hyper stimulation syndrome (OHSS), posing an important medical problem for the clinicians (Humaidan et al., 2010). OHSS is a recognized threat to ovarian stimulation in assisted conception. In a Cochrane review, incidence of OHSS was found to be lower with the use of gonadotrophin releasing hormone (GnRH) antagonist protocol compared with the long down regulation protocol in in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles (Al-Inany et al.,2011). Polycystic ovarian syndrome (PCOS) is one of the most important topics in female reproductive endocrinology (Chen et al., 2007). Women with PCOS undergoing IVF/ICSI treatment are predisposed to developing OHSS due to their high antral follicle count (AFC).The use of Gonadotropin-releasing hormone (GnRH) antagonist protocol rather than the long agonist protocol has demonstrated a significant decrease in the incidence of OHSS (Pundir et al., 2012; Teede et al., 2018). GnRH antagonist, in the last decades, has been introduced to the market to be used for pituitary desensitization in IVF/ICSI treatment cycles. GnRH antagonist protocol is shown to be an effective alternative to the standard long GnRH agonist protocol (Check et al., 1993)
530			_aIssued also as CD
653		4	_aGnRH Agonist trigger versus
653		4	_aHCG trigger in GnRH antagonist
653		4	_aIVF/ICSI cycles
700	0		_aFouad Abdelkader Abohamila , _eSupervisor
700	0		_aMohamed Ahmed Bahaa , _eSupervisor
700	0		_aWafaa Ramadan Abdelrazik , _eSupervisor
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c81541 _d81541